Medication Management in Pregnant Patient with Rheumatic Heart Disease and Heart Failure
Immediately discontinue ACE inhibitors, ARBs, ARNi (angiotensin receptor-neprilysin inhibitors), spironolactone (or any mineralocorticoid receptor antagonists), ivabradine, and SGLT2 inhibitors if the patient is on any of these medications. 1, 2
Medications to DISCONTINUE
The following heart failure medications are contraindicated in pregnancy and must be stopped as soon as pregnancy is confirmed:
- ACE inhibitors (e.g., enalapril, lisinopril)
- Angiotensin receptor blockers (ARBs) (e.g., losartan, valsartan)
- Angiotensin receptor-neprilysin inhibitors (ARNi) (e.g., sacubitril/valsartan)
- Mineralocorticoid receptor antagonists (e.g., spironolactone, eplerenone)
- Ivabradine
- SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin)
These medications carry risks of fetal embryopathy, fetopathy, renal dysfunction, and other teratogenic effects. The urgency of discontinuation cannot be overstated—stop these immediately upon pregnancy confirmation, even if this means temporarily accepting suboptimal heart failure control.
Medications to CONTINUE
Beta-blockers should be continued throughout pregnancy 1, 2. The preferred agents are:
- Metoprolol
- Carvedilol
- Bisoprolol
These are safe in pregnancy and essential for rate control, especially given the risk of atrial fibrillation in rheumatic heart disease with severe MR/TR. Do not discontinue beta-blockers unless the patient develops acute decompensated heart failure requiring inotropic support 2.
Diuretics (furosemide) should be continued as needed for volume management and congestive symptoms 3, 2. Given the severe regurgitant lesions and mild hypokinesia, diuretics will likely be necessary throughout pregnancy.
Safe Alternatives for Afterload Reduction
Since ACE inhibitors/ARBs must be stopped, substitute with hydralazine and/or isosorbide dinitrate for afterload reduction 1, 2. This combination is pregnancy-safe and provides hemodynamic benefit in regurgitant lesions.
Anticoagulation Considerations
Given the rheumatic etiology, assess for:
- Atrial fibrillation: If present, therapeutic anticoagulation is mandatory 3
- Left atrial enlargement/thrombus: Common in rheumatic disease with severe MR
- EF 50% with global hypokinesia: Consider prophylactic anticoagulation
If EF drops below 35% or if atrial fibrillation develops, pharmacologic thromboprophylaxis is recommended throughout pregnancy and for 6 weeks postpartum 2.
Critical Monitoring Points
This patient requires multidisciplinary care at a center with expertise in cardiac disease in pregnancy 1, 2. The combination of:
- Severe valvular disease (MR + TR)
- Reduced systolic function (EF 50% with hypokinesia)
- Rheumatic etiology (risk of progression, atrial fibrillation)
...places her at high risk for decompensation during the hemodynamic stress of pregnancy, particularly in the second trimester and peripartum period.
Common Pitfalls to Avoid
Do not continue spironolactone "just for a few more weeks"—it causes anti-androgenic effects and should be stopped immediately 1
Do not stop beta-blockers thinking they will harm the fetus—they are safe and essential for maternal cardiac stability 1, 2
Do not use ACE inhibitors even briefly in the first trimester—embryopathy risk exists throughout, though renal effects are worse in second/third trimesters 1
Do not forget to reassess the need for valve intervention—severe symptomatic valvular disease may require percutaneous mitral commissurotomy during pregnancy if medical therapy fails 3
Medication Summary Table
| Medication Class | Action | Rationale |
|---|---|---|
| ACE-I/ARB/ARNi | STOP | Teratogenic, fetal renal dysfunction |
| Spironolactone/MRA | STOP | Anti-androgenic effects |
| Ivabradine | STOP | Contraindicated in pregnancy |
| SGLT2 inhibitors | STOP | Contraindicated in pregnancy |
| Beta-blockers | CONTINUE | Safe, essential for rate control |
| Diuretics | CONTINUE | Safe, needed for volume management |
| Hydralazine/Nitrates | ADD | Safe afterload reduction alternative |
The patient should be transitioned to pregnancy-safe medications within days of pregnancy confirmation, with close monitoring for decompensation during the medication switch 1, 2.